US Patent

US10022445 — Patch

Formulation · Assigned to Hisamitsu Pharmaceutical Co Inc · Expires 2033-07-25 · 7y remaining

Vulnerability score 25/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a patch formulation that includes free asenapine, a maleic acid alkali salt, and a rubber-based adhesive agent.

USPTO Abstract

In a patch comprising a support layer and an adhesive agent layer, the adhesive agent layer comprises free asenapine, a maleic acid alkali salt, and a rubber-based adhesive agent.

Drugs covered by this patent

Saphris (ASENAPINE) · Hisamitsu

Patent Metadata

Patent number: US10022445
Jurisdiction: US
Classification: Formulation
Expires: 2033-07-25
Drug substance claim: No
Drug product claim: Yes
Assignee: Hisamitsu Pharmaceutical Co Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.